Skip to Content
Morningstar
Get 14 Days Free

Perrigo Co PLC PRGO

Morningstar Rating
Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Perrigo Unloads Its Generic Business and Reports Softness in Its Fourth Quarter

Soo Romanoff Equity Analyst

Analyst Note

| Soo Romanoff |

No-moat Perrigo reported another quarter with the usual (significant) puts and takes complicated by the announced divestiture of its prescription business further muddied by the pandemic. Management has been active in the M&A market to better configure and manage its offerings across segments. The announced sale of its prescription business will provide the company with approximately $1.55 billion in gross proceeds that will likely aid in funding incremental acquisitions to expand its consumer self-care focus. We do not foresee a significant change in our fair value estimate of $40 per share.

Read Full Analysis

Company Profile

Business Description

Perrigo is the leading provider of over-the-counter generic drugs with over 100 global locations. The company was formed in 1887 as a packager of home remedies and has grown with the migration of prescriptions switching to OTC and later with strategic acquisitions. The company has a portfolio of more than 3,000 product formulations and 14,000 stock-keeping units. Most of its manufacturing and customer base reside in North America. With the most recent management change, the company announced a narrower focus on consumer wellness in conjunction with the divestiture of animal health, acquisition of Ranir Global Holdings, and plans to sell or spin off the prescription business.

Contact
The Sharp Building, Hogan Place
Dublin, D02 TY74, Ireland
T +353 17094000
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Dec 31, 2020
Fiscal Year End Dec 31, 2020
Stock Type —
Employees 11,500

Related

US Videos
Weekly Wrap: Politics in Play in Exelon's Closure Decision
Exelon's decision to close Three Mile Island seems to be aimed at pressuring Pennsylvania to implement nuclear plant credits. Plus, caution with Perrigo, and HP Enterprise's guidance disappoints.
Jeremy Glaser
Stock Analyst Update
Diminished Confidence on Perrigo
Increasing competition in the U.S. generics business and past poor capital-allocation decisions diminish our confidence in future economic profits.
Michael Waterhouse
Stock Strategist Industry Reports
Generic Drug Industry Headwinds Lead to Moat Downgrades
Fear could create opportunity, but we advise investors to proceed with caution.
Michael Waterhouse
Investing Specialists
Top 10 Holdings of Our Ultimate Stock-Pickers' Index
Relatively weak performance from the healthcare sector has created opportunities for long-term investors to consider.
The Morningstar Ultimate Stock-Pickers Team
Investing Specialists
Our Ultimate Stock-Pickers Top 10 New-Money Purchases
While there was much less conviction buying during the second quarter, our top managers did find a few nuggets.
The Morningstar Ultimate Stock-Pickers Team
Investing Specialists
A Deeper Look at Three of Our Top Performing Ultimate Stock-Pickers
Ahead of our conversation with Stephen Yacktman, Dennis Lynch, and Michael Keller at the Morningstar Investment Conference, we examine their top holdings and where they are putting money to work today.
The Morningstar Ultimate Stock-Pickers Team
Investing Specialists
Ultimate Stock-Pickers: Top 10 Buys and Sells
The volatility brought on by concerns over global economic growth in the first quarter presented our top managers with both buying and selling opportunities.
The Morningstar Ultimate Stock-Pickers Team
US Videos
Undervalued Opportunities in Specialty Pharma
Though low earnings multiples are justified for many companies in this beleaguered industry, a handful of players look relatively safe and undervalued at current levels, says Morningstar's Michael Waterhouse.
Michael Waterhouse
Stock Strategist
Akorn On Track
The stock looks undervalued as accounting issues temporarily detract from an attractive business.
Michael Waterhouse
Credit Insights
Dearth of New Issue Supply Allows Corporate Credit Spreads to Tighten
David Sekera
Investing Specialists
Ultimate Stock-Pickers: 10 High-Conviction and New-Money Purchases
The continuing U.S. stock market rally has diminished the number and similarity of purchases across these top managers.
The Morningstar Ultimate Stock-Pickers Team
Stock Strategist
A Shift in Health-Care M&A Activity
Recent deals have been driven more by tax strategies than therapeutic synergies.
Basili Alukos
US Videos
Winners and Losers From the End of the Generic Drugs Wave
As the generics wave crests in the coming years, the dynamics of the pharmaceutical industry will change dramatically, say Morningstar's Matt Coffina and Michael Waterhouse.
Matthew Coffina
Credit Insights
Corporate Bonds Languish as Equity Markets Roar Ahead
Stronger-than-expected economic indicators prompted investors to rethink when the Federal Reserve may begin to taper its asset-purchase program.
David Sekera
ETF Specialist
Heightened Deal Activity Puts Merger-Arbitrage ETFs in Spotlight
Favorable conditions are in place for merger-arbitrage ETFs, including increasing M&A activity and the likelihood of higher interest rates.
Robert Goldsborough
Fund Spy
Funds That Have Thrived on an Apple-Free Diet
It's been hard for large-cap funds to succeed without Apple recently, but a handful of funds have.
Dan Culloton
Stock Strategist Industry Reports
FDA Adapts to an Expanding Generic Drug Industry
The large manufacturers shouldn't have much trouble with the new requirements, though.
Michael Waterhouse
US Videos
Sequoia on the Case for Google
Google's value to users and advertisers, strong cash-flow generation, and current valuation are attractive, says Sequoia's David Poppe. Plus, Poppe outlines the case for newer fund holding Perrigo.
Michael Breen
Stock Strategist Industry Reports
Generic Drugs Fight Uphill Battle in Washington
In the battle between generic and branded biotech, the deck looks increasingly stacked against generics.
Brian Laegeler